AI assistant
Roivant Sciences Ltd. — Regulatory Filings 2023
Oct 4, 2023
30587_rns_2023-10-04_b1b59403-35d9-46ab-9381-68ae5b3f9c53.zip
Regulatory Filings
Open in viewerOpens in your device viewer
CORRESP 1 filename1.htm Licensed to: Broadridge Financial Solutions, Inc. Document created using Broadridge PROfile 23.9.1.5178 Copyright 1995 - 2023 Broadridge
ROIVANT SCIENCES LTD.
7th Floor
50 Broadway
London SW1H 0DB
United Kingdom
October 4, 2023
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E. Washington, D.C. 20549
Attn: Lauren S. Hamill
| Re: |
|---|
| Registration Statement on Form S-3 |
| File No. 333-274804 |
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Roivant Sciences Ltd., a Bermuda exempted limited company (the “Registrant”), hereby requests acceleration of effectiveness of its registration statement on Form S-3 (File No. 333-274804), as amended, to 4:00 p.m. Eastern Time on October 6, 2023, or as soon as practicable thereafter.
The Registrant hereby authorizes Derek J. Dostal and Stephen A. Byeff of Davis Polk & Wardwell LLP to orally modify or withdraw this request for acceleration.
Please contact Derek J. Dostal of Davis Polk & Wardwell LLP at (212) 450-4322 or [email protected] or Stephen A. Byeff of Davis Polk & Wardwell LLP at (212) 450-4715 or [email protected] with any questions you may have concerning this request, and please notify him when this request for acceleration has been granted.
| Very truly yours, ROIVANT SCIENCES LTD. | |
|---|---|
| By: | /s/ Matt Maisak |
| Matt Maisak Authorized Signatory |